Loading patent…
AssigneeThe Government of the U.S.A. as represented by the Secretary of the Dept. of Health & Human Services
InventorsKurt Klimpel, Theresa J. Goletz, Naveen Arora, Stephen H. Leppla, Jay A. Berzofsky
Estimating the term…
The present invention provides a vaccine for inducing an immune response in mammal to a specific antigen, where the vaccine comprises a unit dose of a binary toxin protective antigen and the antigen, which is bound to a binary toxin protective antigen binding protein. In one embodiment the vaccine is comprised of an anthrax protective antigen and the antigen bound to anthrax protective antigen binding protein. The present invention also provides a method of immunizing a mammal against an antigen using the vaccine, and a method of inducing antigen-presenting mammalian cells to present specific antigens via the MHC class I processing pathway.
A vaccine capable of inducing an immune response in a mammal to a specific antigen wherein the vaccine comprises a unit dose of an anthrax protective antigen and said specific antigen bound to an anthrax protective antigen binding protein.
A method of immunizing a mammal against an antigen which comprises administering a safe and effective amount of a vaccine comprising an anthrax protective antigen and said antigen bound to an anthrax protective antigen binding protein.
A method of inducing antigen presenting mammalian cells to present specific antigens on their cell membranes via the MHC class I processing pathway, comprising:
A vaccine for inducing an immune response in a mammal to a specific antigen wherein the vaccine comprises a unit dose of a binary toxin protective antigen and the antigen bound to a binary toxin protective antigen binding protein wherein the binary toxin is selected from the group comprising iota toxin and anthrax toxin.
Dependencies are inferred from the claim text.